The total number of records retrieved from this search are 15. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_639	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result105% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_640	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result107% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_641	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_642	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result70% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_643	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result61% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_644	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result90% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_645	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result93% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_646	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result87% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_647	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result58% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_648	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result59% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_689	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result120% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_690	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result126% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_691	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result92% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_692	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result72% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_693	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineMeWo	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result61% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486